Neuroectodermal elements are part of the morphological spectrum of DICER1-associated neoplasms

Pleuropulmonary blastoma (PPB) and other DICER1-associated high-grade malignancies are morphologically, genetically and epigenetically related – A comparative study of 4 PPBs and 6 sarcomas

“…(Neuro)epithelial structures can also be encountered [20,21,26]. The morphology of our PPBs and sarcomas is in concordance with these observations.…”

“…In addition, a rhabomyoblastic component and fetal-like or sarcomatous cartilage may be characteristically identified [1]. (Neuro)epithelial structures are described mainly in lesions called malignant teratoma or teratoid neoplasm, but have also been reported in other DICER1-associated malignancies [20,21,26].…”

Pleuropulmonary Blastoma (PPB) and Other DICER1-Associated High-Grade Malignancies are Morphologically, Genetically and Epigenetically Related – A Comparative Study of 4 PPBs and 6 Sarcomas

“…(Neuro)epithelial structures can also be encountered [20,21,26]. The morphology of our PPBs and sarcomas is in concordance with these observations.…”

“…In addition, a rhabomyoblastic component and fetal-like or sarcomatous cartilage may be characteristically identified [1]. (Neuro)epithelial structures are described mainly in lesions called malignant teratoma or teratoid neoplasm, but have also been reported in other DICER1-associated malignancies [20,21,26].…”

From Malignant Thyroid Teratoma to Thyroblastoma: Evolution of a Newly-recognized DICER1-associated Malignancy

“…As the spectrum of tumors with DICER1 mutations has expanded, there has been increasing recognition that these entities consistently harbor similar elements despite arising at disparate anatomic sites. [74][75][76][77] Across organs, DICER1-mutated neoplasms frequently include (1) cellular mesenchymal proliferations with variable rhabdomyoblastic differentiation, (2) primitive neuroepithelial blastema, (3) islands of immature cartilage or bone, and (4) epithelium with differentiation toward the organ of origin. Practically speaking, distinguishing between the numerous entities defined by DICER1 mutations should be straightforward on the basis of the location of the tumor, the differentiation of the epithelial elements, and relevant clinical history.…”